Long-term follow-up of the SBG 9401 study comparing tailored FEC-based therapy versus marrow-supported high-dose therapyNils Wilking, Jonas Bergh, Pirkko Kellokumpu‐Lehtinen et al.|Annals of Oncology|2007Cited by 36
High-dose chemotherapy with autologous stem cell support in patients with responding stage IV breast cancerPer Ljungman, Jonas Bergh, Bo Björkstrand et al.|Bone Marrow Transplantation|1998Cited by 10
A randomized feasibility/phase II study (SBG 2004-1) with dose-dense/tailored epirubicin, cyclophoshamide (EC) followed by docetaxel (T) or fixed dosed dose-dense EC/T versus T, doxorubicin and C (TAC) in node-positive breast cancerSara Margolin, Jonas Bergh, Dagny Pettersson et al.|European Journal of Cancer Supplements|2008Cited by 0